BJH - volume 11, issue 5, september 2020
M.C. Vekemans MD
For the first time, in the context of the COVID-19 pandemic, the annual congress of EHA was turned into a full virtual edition, focusing on haematological innovations and evidence-based knowledge of primary clinical evidence. We choose to report ten abstracts of clinical interest that may have a direct impact on our daily practice.
(BELG J HEMATOL 2020;11(5):197-202)
Read moreBJH - volume 11, issue Abstract Book BHS, february 2020
G. Verstraete MD, I. Dufour , J. Raedemaeker , F. Andreozzi , L. Bamps , S. Chabert , A. Sogorb , N. Kanaan , M. De Meyer , A. Buemi , S. Aydin , M.C. Vekemans MD
BJH - volume 11, issue Abstract Book BHS, february 2020
J. Raedemaeker , F. Andreozzi , I. Dufour , L. Bamps , G. Verstraete MD, S. Chabert , S. Bailly MD, D. Maisin , J-P. Defour PhD, A. Camboni MD, PhD, dr. A-C. Pouleur , B. Gerber , F. Lecouvet , M.C. Vekemans MD
BJH - volume 11, issue Abstract Book BHS, february 2020
I. Dufour , G. Verstraete MD, J. Raedemaeker , F. Andreozzi , L. Bamps , S. Chabert , A. Sogorb , S. Bailly MD, E. Van den Neste MD, PhD, X. Theunssens , F. Tamirou , D. Tennstedt , A. Camboni MD, PhD, M.C. Vekemans MD
BJH - volume 11, issue Abstract Book BHS, february 2020
K. Bennis , T. Schubert , F. Jamar , D. Maisin , A. Camboni MD, PhD, S. Aydin , F. Lecouvet , M.C. Vekemans MD
BJH - volume 11, issue Abstract Book BHS, february 2020
F. Andreozzi , I. Dufour , A. Sogorb , S. Chabert , G. Verstraete MD, J. Raedemaeker , L. Bamps , S. Bailly MD, F. Jamar , F. Lecouvet , A. Camboni MD, PhD, J-P. Defour PhD, dr. A-C. Pouleur , J. Morelle MD, PhD, M.C. Vekemans MD
BJH - volume 10, issue 1, february 2019
M.C. Vekemans MD
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic malignancies characterized by peripheral blood cytopenias resulting from ineffective hematopoiesis. MDS is associated with a risk for progression to acute myeloid leukemia (AML). Progress in the field of this disease aims at decreasing the transfusion burden, delaying progression to AML, improving the quality-of-life (QoL) of patients and extending the survival. Here, we report some recent advances presented at the 60th Annual Meeting of the American Society of Hematology (ASH).
(BELG J HEMATOL 2019;10(1):24–30)
Read more
Top
